Revelation Biosciences 3Q 2026: EPS ($5.92) — 10-Q Summary
Revelation Biosciences reported a wider quarterly net loss than a year earlier as research and development and general and administrative expenses increased. The company said higher GEM-AKI program and manufacturing costs, increased personnel expenses and professional fees drove the expense growth…
Story updates
10:33:31 PM UTC
SquawkNews
Revelation Biosciences reported a net loss of $3.3 million for the three months ended September 30, 2026, and a net loss of $9.6 million for the first nine months of the year. The company had $9.1 million in cash and cash equivalents at quarter-end and said its cash was expected to fund operations…